Mark James Litton - Oct 3, 2024 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
President and CEO, Director
Signature
/s/ Mark Worthington, Attorney-in-Fact for Mark James Litton
Stock symbol
ATHA
Transactions as of
Oct 3, 2024
Transactions value $
$0
Form type
4
Date filed
10/3/2024, 07:07 PM
Previous filing
Sep 5, 2024
This filing has been restated, see here for the amended filing

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Restricted Stock Units Award $0 +325K $0.00 325K Oct 3, 2024 Common Stock 325K Direct F1, F2
transaction ATHA Stock Option (Right to Buy) Award $0 +325K $0.00 325K Oct 3, 2024 Common Stock 325K $0.45 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.
F2 One-third (1/3rd) of the RSUs shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates.
F3 One-third (1/3rd) of the shares subject to the option shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider through the applicable vesting dates.